NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.82% | 14.63% | 8.33% | 0.61% | -5.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.82% | 14.63% | 8.33% | 0.61% | -5.30% |
| Cost of Revenue | 6.77% | 9.25% | 8.66% | 13.27% | 11.62% |
| Gross Profit | 22.85% | 16.39% | 8.23% | -3.01% | -9.86% |
| SG&A Expenses | 10.40% | 0.56% | 7.91% | 16.84% | 26.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.07% | 0.06% | 4.12% | 8.98% | 17.35% |
| Operating Income | 25.92% | 32.81% | 7.13% | -38.45% | -154.36% |
| Income Before Tax | 31.59% | 38.37% | 12.32% | -32.12% | -134.27% |
| Income Tax Expenses | 144.82% | 206.82% | 105.78% | 93.98% | 43.18% |
| Earnings from Continuing Operations | 18.55% | 24.07% | 3.25% | -36.75% | -123.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.55% | 24.07% | 3.25% | -36.75% | -123.75% |
| EBIT | 25.92% | 32.81% | 7.13% | -38.45% | -154.36% |
| EBITDA | 27.16% | 34.18% | 7.62% | -41.05% | -172.81% |
| EPS Basic | 19.77% | 25.11% | 4.62% | -34.68% | -120.46% |
| Normalized Basic EPS | 27.13% | 30.74% | 4.48% | -39.00% | -142.05% |
| EPS Diluted | 19.76% | 25.11% | 4.61% | -34.63% | -120.34% |
| Normalized Diluted EPS | 27.13% | 30.74% | 4.48% | -39.00% | -142.05% |
| Average Basic Shares Outstanding | 1.40% | 1.52% | 1.62% | 1.69% | 1.67% |
| Average Diluted Shares Outstanding | 1.40% | 1.52% | 1.62% | 1.69% | 1.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |